ASTH

Rating neutralAI MemoPost-earnings T+3

Astrana Health

As of 2026-05-09/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Prospect integration and full-risk contract conversion need another quarter of proof • 2026-11-05

Expected move: -6%

Biggest risk

The bear read is that a large share of the growth still reflects acquired revenue, medical liabilities rose to $439.3M, long-term debt remained near $979.8M, and the previously disclosed material weakness in business-combination accounting was still not remediated as of March 31, 2026, limiting how much investors should pay for the story today [#10-Q-2026-05-08].

Invalidation

Break below $28 or thesis failure.

What would change my mind?

The post-earnings bull read is straightforward: Q1 showed 56% revenue growth, 82% adjusted EBITDA growth, strong free cash flow, reiterated guidance, and early evidence that full-risk contract conversions and Prospect integration are tracking acceptably [#8-K-2026-05-07].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-09

Base target

$36

p=50%

Bull target

$46

p=25%

Bear target

$28

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 and full-year execution against reiterated outlook
Free-cash-flow and deleveraging path could support a rerating if controls improve
The post-earnings bull read is straightforward: Q1 showed 56% revenue growth, 82% adjusted EBITDA growth, strong free cash flow, reiterated guidance, and early evidence that full-risk contract conversions and Prospect integration are tracking acceptably [#8-K-2026-05-07].

BearKey bullets

A large portion of the quarter's revenue growth came from the Prospect acquisition, so any integration miss or weaker-than-expected contribution could pressure the earnings-power narrative [#10-Q-2026-05-08].
Leverage is still meaningful, with about $979.8M of long-term debt and covenant requirements that become tighter over time [#10-Q-2026-05-08].
Material weakness in internal control over financial reporting tied to business-combination accounting remained unremediated as of March 31, 2026 [#10-Q-2026-05-08].

WatchKey bullets

Prospect integration and full-risk contract conversion need another quarter of proof

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $36 (p=50%)

Bull/Bear spread: +20% / -27%

Vs latest close: Bull +20% · Base -6% · Bear -27%

Scenario probabilities

Bull Target: $46 (p=25%)Base Target: $36 (p=50%)Bear Target: $28 (p=25%)

Commentary

This is still a monitoring-style post-earnings memo, not a high-conviction upgrade. The primary company release and 10-Q support a better near-term operating read, and the stock appeared to confirm that initially: by May 9, 2026, ASTH traded at $39.30 versus a $36.03 prior close, about a 9% move higher. But the deterministic prior remains negative, catalyst density is still only modest, and checked sources did not provide a dependable T+3 analyst-revision slate, so the positive price reaction should not be treated as full thesis validation yet.

As of 2026-05-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 and full-year execution against reiterated outlook
Free-cash-flow and deleveraging path could support a rerating if controls improve

Scenarios

Bull Target (Scenario probability)

$46 / p=25% prob

Base Target (Scenario probability)

$36 / p=50% prob

Bear Target (Scenario probability)

$28 / p=25% prob

Price $38 as of 2026-07-27

Nearest Scenario: Base (∆ 6%)

Targets vs latest close: Bull +20% · Base -6% · Bear -27%

Sentiment & Exposure

News Sentiment (30d)

0.20

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-05
Prospect integration and full-risk contract conversion need another quarter of proof
The 10-Q attributes much of the year-over-year revenue increase to the Prospect acquisition, which contributed $300.2M of revenue in the quarter, while also citing revenue lift from members transitioning to full risk through Restricted Knox-Keene plans. Management also highlighted that about 80% of Care Partners capitation revenue and about 40% of consolidated membership are now in full-risk arrangements, including a Texas payer launch above 14,000 Medicare Advantage members. If this expansion holds with stable medical cost performance, the market can support a better earnings-power view; if integration, utilization, or reserve assumptions slip, sentiment can reverse quickly [#10-Q-2026-05-08] [#8-K-2026-05-07].
Prob 60.00% • Move 14.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Q2 and full-year execution against reiterated outlook
2026-08-06
Q1 revenue of $965.1M and adjusted EBITDA of $66.3M came in strong enough for management to reiterate Q2 revenue guidance of $965M-$1.0B, Q2 adjusted EBITDA of $65M-$70M, and full-year revenue of $3.8B-$4.1B with adjusted EBITDA of $250M-$280M. The next print now matters more than the headline beat because the stock already reacted positively and the setup shifts to proving that post-Prospect growth, margin discipline, and cash conversion are sustainable [#8-K-2026-05-07].
Prob 70% • Move 10% • Priced-in 60%

Long-term Catalysts

Months to a year

Free-cash-flow and deleveraging path could support a rerating if controls improve
2027-03-31
Astrana reported Q1 operating cash flow of $68.1M and free cash flow of $64.1M, while highlighting net leverage of roughly 2.3x on a pro forma trailing basis and 2.2x versus the midpoint of full-year guidance. The longer-duration upside case is that recurring cash generation, debt paydown, and a broader physician-network platform translate into a cleaner multiple; however, that case still competes with unresolved internal-control remediation and acquisition-accounting complexity [#8-K-2026-05-07] [#10-Q-2026-05-08].
Prob 45% • Move 24% • Priced-in 30%

Risks

A large portion of the quarter's revenue growth came from the Prospect acquisition, so any integration miss or weaker-than-expected contribution could pressure the earnings-power narrative [#10-Q-2026-05-08].
Leverage is still meaningful, with about $979.8M of long-term debt and covenant requirements that become tighter over time [#10-Q-2026-05-08].
Material weakness in internal control over financial reporting tied to business-combination accounting remained unremediated as of March 31, 2026 [#10-Q-2026-05-08].
Medical liabilities ended Q1 at $439.3M, leaving the story sensitive to utilization, reserve accuracy, and claims-payment timing [#10-Q-2026-05-08].

Peers

Symbol	Summary
CLOV	Clover Health remains the closest packet peer because both narratives depend on value-based care economics and technology-enabled care management, though Clover still carries a more insurance-heavy profile than Astrana.
AHCO	AdaptHealth is an adjacent healthcare-services comp for reimbursement and operating-execution sensitivity, but it is not a direct read-through for delegated-risk physician-network scaling.
ACHC	Acadia is mainly a discipline and execution comparator rather than a business-model peer, so it is useful only as a loose services benchmark.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-09

AI Stock Memo: ASTH - Astrana Health - RankAlpha